Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 7-8/2021

09.12.2020 | original article

Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19

verfasst von: MD, PhD Satoru Chiba

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Since December 2019 coronavirus disease 2019 (COVID-19) outbreaks have occurred in China and many countries around the world. The effectiveness of oseltamivir on COVID-19 suspected outpatients without hypoxia was evaluated.

Methods

A total of 16 COVID-19 suspected medical personnel and their cohabitation families without hypoxia, who came to the adult fever clinic from March to June 2020 were studied. All patients received antiviral therapy (oseltamivir) and antibacterial therapy together.

Results

Most of the infected patients were female (10, 63%), 1 had diabetes (6%) and 3 hypertension (19%). The median age was 45 years (interquartile range [IQR] 31–60 years). Oseltamivir administration made the temperature fall within 24 h in part (10, 63%). Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 h, and patients administered late treatment (LT), initiated after this time point. Duration of fever was shorter in the ET group than in the LT group (31 ± 21 h versus 94 ± 38 h; p < 0.001). The time from fever onset to treatment initiation correlated with duration of fever (r = 0.77; p < 0.001) and the time from peak to decline (r = 0.58; p < 0.05).

Conclusion

These findings suggest that early oseltamivir administration may lower the duration of fever in COVID-19 suspected outpatients without hypoxia when it is used in combination with antibacterial therapy.
Literatur
1.
Zurück zum Zitat Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924. CrossRef Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924. CrossRef
2.
Zurück zum Zitat Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020;19:105948. CrossRef Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020;19:105948. CrossRef
4.
Zurück zum Zitat Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. CrossRef Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. CrossRef
5.
Zurück zum Zitat Guangdi L, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–50. CrossRef Guangdi L, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–50. CrossRef
6.
Zurück zum Zitat Khamitov RA, Loginova SLA, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian. Vopr Virusol. 2008;53(4):9–13. PubMed Khamitov RA, Loginova SLA, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian. Vopr Virusol. 2008;53(4):9–13. PubMed
7.
Zurück zum Zitat Al-Tawfiq JA, Rabaan AA, Hinedi K. Influenza is more common than Middle East Respiratory Syndrome Coronavirus (MERS-CoV) among hospitalized adult Saudi patients. Travel Med Infect Dis. 2017;20:56–60. CrossRef Al-Tawfiq JA, Rabaan AA, Hinedi K. Influenza is more common than Middle East Respiratory Syndrome Coronavirus (MERS-CoV) among hospitalized adult Saudi patients. Travel Med Infect Dis. 2017;20:56–60. CrossRef
8.
Zurück zum Zitat Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. CrossRef Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. CrossRef
9.
Zurück zum Zitat Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T, et al. Evaluation of twenty-two rapid antigen detection tests in the diagnosis of Equine Influenza caused by viruses of H3N8 subtype. Influenza Other Respir Viruses. 2016;10:127–33. CrossRef Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T, et al. Evaluation of twenty-two rapid antigen detection tests in the diagnosis of Equine Influenza caused by viruses of H3N8 subtype. Influenza Other Respir Viruses. 2016;10:127–33. CrossRef
10.
Zurück zum Zitat IMPACT Study Group, Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123–9. CrossRef IMPACT Study Group, Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123–9. CrossRef
11.
Zurück zum Zitat Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6. CrossRef Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6. CrossRef
12.
Zurück zum Zitat Ono H, Iwajima Y, Nagano Y, Chazono K, Maeda Y, Ohsawa M, et al. Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice. Basic Clin Pharmacol Toxicol. 2013;113(1):25–30. CrossRef Ono H, Iwajima Y, Nagano Y, Chazono K, Maeda Y, Ohsawa M, et al. Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice. Basic Clin Pharmacol Toxicol. 2013;113(1):25–30. CrossRef
13.
Zurück zum Zitat Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic Coronavirus disease 2019 (COVID-19). Cureus. 2020;12(4):e7560. PubMedPubMedCentral Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic Coronavirus disease 2019 (COVID-19). Cureus. 2020;12(4):e7560. PubMedPubMedCentral
14.
Zurück zum Zitat Some Drugs for COVID-19, Med Lett Drugs Ther 2020 Apr 6;62(1595):49–50. Some Drugs for COVID-19, Med Lett Drugs Ther 2020 Apr 6;62(1595):49–50.
15.
Zurück zum Zitat Coenen S, van der Velden AW, Cianci D, Goossens H, Bongard E, Saville BR, et al. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018. Br J Gen Pract. 2020;70(696):e444–e9. CrossRef Coenen S, van der Velden AW, Cianci D, Goossens H, Bongard E, Saville BR, et al. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018. Br J Gen Pract. 2020;70(696):e444–e9. CrossRef
16.
Zurück zum Zitat Patra JK, Das G, Bose S, Banerjee S, Vishnuprasad CN, Del Pilar Rodriguez-Torres M, et al. Star anise (Illicium verum): chemical compounds, antiviral properties, and clinical relevance. Phytother Res. 2020;34(6):1248–67. CrossRef Patra JK, Das G, Bose S, Banerjee S, Vishnuprasad CN, Del Pilar Rodriguez-Torres M, et al. Star anise (Illicium verum): chemical compounds, antiviral properties, and clinical relevance. Phytother Res. 2020;34(6):1248–67. CrossRef
17.
Zurück zum Zitat Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. CrossRef Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. CrossRef
18.
Zurück zum Zitat Sheng ZM, Chertow DS, Ambroggio X, McCall S, Przygodzki RM, Cunningham RE, et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci U S A. 2011;108(39):16416–21. CrossRef Sheng ZM, Chertow DS, Ambroggio X, McCall S, Przygodzki RM, Cunningham RE, et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci U S A. 2011;108(39):16416–21. CrossRef
19.
Zurück zum Zitat Zusso M, Lunardi V, Franceschini D, Pagetta A, Lo R, Stifani S, et al. Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. J Neuroinflammation. 2019;16(1):148. CrossRef Zusso M, Lunardi V, Franceschini D, Pagetta A, Lo R, Stifani S, et al. Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. J Neuroinflammation. 2019;16(1):148. CrossRef
Metadaten
Titel
Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19
verfasst von
MD, PhD Satoru Chiba
Publikationsdatum
09.12.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01780-0